ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst_老虎社区_美港股上老虎

ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst

investorplace2021-06-17

The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

eyescold
·2021-06-20
👍
回复
1
举报
WilliamWCW
·2021-06-18
👍
回复
点赞
举报
Marco0os
·2021-06-17
Time to buy in
回复
1
举报
Guat65
·2021-06-17
Haj
回复
1
举报
收起
- Xav:
  HaJ
  2021-06-17
  回复
  举报
PanaCota
·2021-06-17
Like n comment pls
回复
2
举报
Liangwayne
·2021-06-17
What’s with the recent hype on ORPH?
回复
点赞
举报
Rocket2Mars
·2021-06-17
Go!
回复
2
举报
Kwgan
·2021-06-17
Oops
回复
2
举报
收起
- AllanLaw7878:
  ☺️
  2021-06-17
  回复
  举报
Clow
·2021-06-17
👌👍
回复
2
举报
收起
- ALJ:
  Comment back
  2021-06-17
  回复
  举报
- Ivanhojh:
  Comment back pls
  2021-06-17
  回复
  举报
Tida
·2021-06-17
Shock
回复
1
举报
AshlynCasper
·2021-06-17
Wooohoooo. Cant wait!
回复
点赞
举报
Jellibean
·2021-06-17
Can’t wait for it to boom tonight!!!!
回复
2
举报
收起
- Liangwayne:
  Whats the hype about?
  2021-06-17
  回复
  举报
- Jellibean:
  Tomight the FDA will be announced.
  2021-06-18
  回复
  举报
TeslaLegend
·2021-06-17
Tell me your opinion about this news...
回复
1
举报
boonchek
·2021-06-17
Comment back
回复
1
举报
收起
- TeslaLegend:
  Nice
  2021-06-17
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1103057922?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-06-17 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103057922","market":"us","top_or_hot":-1,"title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","media":"investorplace","content":"<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">网页链接</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","article_id":"1103057922","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","pubTimestamp":1623916087,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"ORPH股票：在6月17日催化剂之前，Orphazyme再次流行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORPH":0.9},"content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":164378054,"gmtCreate":1624175647078,"gmtModify":1634009770277,"author":{"id":"3582062230385855","authorId":"3582062230385855","name":"eyescold","avatar":"https://static.tigerbbs.com/947cfb8056822e3c4b4c3ace4c59dd6f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582062230385855","authorIdStr":"3582062230385855"},"htmlText":"👍&nbsp;","listText":"👍&nbsp;","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164378054","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":168300830,"gmtCreate":1623948538020,"gmtModify":1634025353021,"author":{"id":"3573693462129192","authorId":"3573693462129192","name":"WilliamWCW","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573693462129192","authorIdStr":"3573693462129192"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168300830","repostId":1103057922,"repostType":2,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161827444,"gmtCreate":1623919066788,"gmtModify":1631885484325,"author":{"id":"3575372039876731","authorId":"3575372039876731","name":"Marco0os","avatar":"https://static.tigerbbs.com/d46598c0c790e4ea6b524daef7d5f0d1","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3575372039876731","authorIdStr":"3575372039876731"},"htmlText":"Time to buy in","listText":"Time to buy in","text":"Time to buy in","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161827444","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161826132,"gmtCreate":1623918850626,"gmtModify":1634025889879,"author":{"id":"3569745941427325","authorId":"3569745941427325","name":"Guat65","avatar":"https://static.tigerbbs.com/93d2135fbec26685c7a7aa6e923c9ac3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569745941427325","authorIdStr":"3569745941427325"},"htmlText":"Haj","listText":"Haj","text":"Haj","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/161826132","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4836345,"gmtCreate":1623918936690,"gmtModify":1635313950939,"authorId":3552300010636249,"author":{"id":3552300010636249,"idStr":"3552300010636249","authorId":3552300010636249,"name":"Xav","avatar":"https://static.tigerbbs.com/0a3685fb5cad038c0cc06fad33863aeb","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161826132,"type":1,"supId":0,"prevId":0,"content":"HaJ","text":"HaJ","html":"HaJ"}],"langContent":"EN"},{"id":161820320,"gmtCreate":1623918580960,"gmtModify":1634025892206,"author":{"id":"3581588474178431","authorId":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581588474178431","authorIdStr":"3581588474178431"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161820320","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161887331,"gmtCreate":1623917864323,"gmtModify":1634025898306,"author":{"id":"3581545292648790","authorId":"3581545292648790","name":"Liangwayne","avatar":"https://static.tigerbbs.com/c7725872cc63bfc4a00710c540d2fa75","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581545292648790","authorIdStr":"3581545292648790"},"htmlText":"What’s with the recent hype on ORPH?","listText":"What’s with the recent hype on ORPH?","text":"What’s with the recent hype on ORPH?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161887331","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161888200,"gmtCreate":1623917591500,"gmtModify":1631888990695,"author":{"id":"3578399462882565","authorId":"3578399462882565","name":"Rocket2Mars","avatar":"https://static.tigerbbs.com/a98299f891ae0ae35c465cedc8c17d36","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3578399462882565","authorIdStr":"3578399462882565"},"htmlText":"Go!","listText":"Go!","text":"Go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161888200","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161889663,"gmtCreate":1623917417152,"gmtModify":1634025903362,"author":{"id":"3555113831623017","authorId":"3555113831623017","name":"Kwgan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3555113831623017","authorIdStr":"3555113831623017"},"htmlText":"Oops&nbsp;","listText":"Oops&nbsp;","text":"Oops","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/161889663","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4835917,"gmtCreate":1623917454684,"gmtModify":1635313983394,"authorId":3581822921647319,"author":{"id":3581822921647319,"idStr":"3581822921647319","authorId":3581822921647319,"name":"AllanLaw7878","avatar":"https://static.tigerbbs.com/63d32a493c541f1a5760a4140e8835e9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161889663,"type":1,"supId":0,"prevId":0,"content":"☺️","text":"☺️","html":"☺️"}],"langContent":"EN"},{"id":161880132,"gmtCreate":1623917337226,"gmtModify":1634025904272,"author":{"id":"3579597581777598","authorId":"3579597581777598","name":"Clow","avatar":"https://static.tigerbbs.com/410ae1529dc71fa5dac38e9185b7ee2c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3579597581777598","authorIdStr":"3579597581777598"},"htmlText":"👌👍","listText":"👌👍","text":"👌👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/161880132","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4835896,"gmtCreate":1623917395774,"gmtModify":1635313984961,"authorId":3580369297405098,"author":{"id":3580369297405098,"idStr":"3580369297405098","authorId":3580369297405098,"name":"ALJ","avatar":"https://static.tigerbbs.com/09cf26739408be1e66df79a687197ca5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161880132,"type":1,"supId":0,"prevId":0,"content":"Comment <u>back</u>","text":"Comment <u>back</u>","html":"Comment <u>back</u>"},{"id":4835950,"gmtCreate":1623917567886,"gmtModify":1635313980542,"authorId":3575241823069388,"author":{"id":3575241823069388,"idStr":"3575241823069388","authorId":3575241823069388,"name":"Ivanhojh","avatar":"https://static.tigerbbs.com/a41f0bf4ce9ad13477b3d5ba49c8d025","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161880132,"type":1,"supId":4835896,"prevId":0,"content":"Comment back pls","text":"Comment back pls","html":"Comment back pls"}],"langContent":"EN"},{"id":161818094,"gmtCreate":1623917047118,"gmtModify":1634025908047,"author":{"id":"3583821827943481","authorId":"3583821827943481","name":"Tida","avatar":"https://static.tigerbbs.com/396dd2343dccd2b111b76f8d4eed1512","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3583821827943481","authorIdStr":"3583821827943481"},"htmlText":"Shock","listText":"Shock","text":"Shock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161818094","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161819891,"gmtCreate":1623916885613,"gmtModify":1634025910179,"author":{"id":"3585001213253441","authorId":"3585001213253441","name":"AshlynCasper","avatar":"https://static.tigerbbs.com/487c76350755814108576115620cc523","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585001213253441","authorIdStr":"3585001213253441"},"htmlText":"Wooohoooo. Cant wait!","listText":"Wooohoooo. Cant wait!","text":"Wooohoooo. Cant wait!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161819891","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161838841,"gmtCreate":1623916485483,"gmtModify":1634025915262,"author":{"id":"3583497216814073","authorId":"3583497216814073","name":"Jellibean","avatar":"https://static.tigerbbs.com/0f26ac2cfca73b4b1f7095f962e61487","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583497216814073","authorIdStr":"3583497216814073"},"htmlText":"Can’t wait for it to boom tonight!!!!","listText":"Can’t wait for it to boom tonight!!!!","text":"Can’t wait for it to boom tonight!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/161838841","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4836054,"gmtCreate":1623917895692,"gmtModify":1635313971544,"authorId":3581545292648790,"author":{"id":3581545292648790,"idStr":"3581545292648790","authorId":3581545292648790,"name":"Liangwayne","avatar":"https://static.tigerbbs.com/c7725872cc63bfc4a00710c540d2fa75","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161838841,"type":1,"supId":0,"prevId":0,"content":"Whats the hype about?","text":"Whats the hype about?","html":"Whats the hype about?"},{"id":4855213,"gmtCreate":1623980759776,"gmtModify":1635312227208,"authorId":3583497216814073,"author":{"id":3583497216814073,"idStr":"3583497216814073","authorId":3583497216814073,"name":"Jellibean","avatar":"https://static.tigerbbs.com/0f26ac2cfca73b4b1f7095f962e61487","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161838841,"type":1,"supId":0,"prevId":0,"content":"Tomight the FDA will be announced.","text":"Tomight the FDA will be announced.","html":"Tomight the FDA will be announced."}],"langContent":"EN"},{"id":161831881,"gmtCreate":1623916460243,"gmtModify":1634025915869,"author":{"id":"3572489627147183","authorId":"3572489627147183","name":"TeslaLegend","avatar":"https://static.tigerbbs.com/180ad6f06095bcbf2b6594d26c494752","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3572489627147183","authorIdStr":"3572489627147183"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161831881","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":161831920,"gmtCreate":1623916453660,"gmtModify":1634025915990,"author":{"id":"3582036219515358","authorId":"3582036219515358","name":"boonchek","avatar":"https://static.tigerbbs.com/c615abbfde8feafcbdd8e88179f1e152","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582036219515358","authorIdStr":"3582036219515358"},"htmlText":"Comment back","listText":"Comment back","text":"Comment back","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/161831920","repostId":1103057922,"repostType":4,"repost":{"id":"1103057922","pubTimestamp":1623916087,"share":"https://www.laohu8.com/m/news/1103057922?lang=&edition=full","pubTime":"2021-06-17 15:48","market":"us","language":"en","title":"ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1103057922","media":"investorplace","summary":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazym","content":"<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company&nbsp;<b>Orphazyme</b>(NASDAQ:<b><u>ORPH</u></b>) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.</p>\n<p>Trading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.</p>\n<p>The U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.</p>\n<p>The company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.</p>\n<p>ORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nORPH Stock: What to Know as Orphazyme Pops Again Ahead of June 17 Catalyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 15:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last ...</p>\n\n<a href=\"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/orph-stock-what-to-know-as-orphazyme-pops-again-ahead-of-june-17-catalyst/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103057922","content_text":"The meme stock crowd have their sights set on new targets and orphan drug treatment company Orphazyme(NASDAQ:ORPH) is up nearly 90% today as a result. ORPH stock has been trading jaggedly since last week,at one point up more than 1,000% on Friday, June 11.\nTrading volume of 115 million shares on the day at time of writing was dramatically up from an average daily trading volume of 1.3 million. Orphazyme management released a press release on Friday saying there wasno reason for the stock movement.\nThe U.S. Food and Drug Administration has set areview date of June 17 for ORPH stock’s key drug candidate ariclomal, which will be used to treat Niemann-Pick Disease Type C.\nThe company is also exploring the efficacy of ariclomal in treating other orphan diseases, though that endeavor hasn’t yielded positive results yet. Two different Phase 2/3 trials for treatment ofInclusion Body MyositisandAmyotrophic Lateral Sclerosisdid not meet their primary and secondary endpoints. In the company’s 2020 annual report, released in March 2021,addressable markets for IBM and ALS made up 45,000 of 62,000 patientsacross the four diseases discussed.\nORPH stock is presently covered by two analysts, with aprice consensus of $16. That’s more than 15% lower than its current price of $18.88.Meme stock traders have announced their intentionto send Orphazyme to the moon, but it’s hard to believe the stock won’t deflate following FDA results, even if positive.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4835702,"gmtCreate":1623916471627,"gmtModify":1635314001418,"authorId":3572489627147183,"author":{"id":3572489627147183,"idStr":"3572489627147183","authorId":3572489627147183,"name":"TeslaLegend","avatar":"https://static.tigerbbs.com/180ad6f06095bcbf2b6594d26c494752","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":161831920,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":66,"commentSize":14,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}